Boston, USA-based Verastem Oncology will present updated interim results from Part A of the Phase II RAMP 201 study of avutometinib and defactinib at this year’ 19 May 2023
Swiss financial group Cedrus is to collaborate with Chinese pharma giant Xiuzheng Pharmaceutical to identify investment opportunities in China. 16 May 2023
Ireland’s health technology assessor, the National Centre for Pharmacoeconomics (NCPE), has awarded a positive reimbursement decision to the oral anti-seizure m 15 May 2023
Koselugo (selumetinib) has been approved in China for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofib 9 May 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.